Bruce Levine
University of Pennsylvania

BRUCE LEVINE is the Barbara and Edward Netter professor in cancer gene therapy and the founding director of the Clinical Cell and Vaccine Production Facility at the Perelman School of Medicine at the University of Pennsylvania. He received a B.A. from the University of Pennsylvania and a Ph.D. from Johns Hopkins University. Levine is a pioneer in the field of CAR T-cell therapies, including the first-in-human adoptive immunotherapy trials to use a lentiviral vector; the first infusions of gene-edited cells; and the first use of lentivirally modified cells to treat cancer. Levine is co-inventor of the first Food and Drug Administration-approved CAR T-cell therapy for leukemia and lymphoma (Kymriah, licensed to Novartis). 

Levine is co-inventor on 33 patents and co-author of more than 200 manuscripts and book chapters with a Google Scholar citation h-index of 114. He is a co-founder of Tmunity Therapeutics and Capstan Therapeutics. Levine is a recipient of the William Osler Patient Oriented Research Award, the Wallace H. Coulter Award for Healthcare Innovation, the 2020 National Marrow Donor Program/Be The Match Dennis Confer Innovate Award, the 2023 American Society of Gene and Cell Therapy Jerry Mendell Award for Translational Science, and the International Society for Cell & Gene Therapy Career Achievement Award in Cell and Gene Therapy. 

Photo courtesy of University of Pennsylvania Perelman School of Medicine